Concepedia

Nitin Nair

NN

Statistics

Publications

26

Citations

3.7K

H-Index

19

Active since

1970

Affiliations

Vertex Pharmaceuticals (United States)(Current)

New York University

Takeda (United States)

St. Vincent's University Hospital

University of Toronto

Nitin Nair is an author at Vertex Pharmaceuticals (United States) specializing in pharmacology, pharmacy, and pharmacotherapy.

Publications per year

1970–2025

26

Publications

26

Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

Peter G. Middleton, Marcus Mall, Pavel Dřevı́nek et al. · New England Journal of Medicine · 2019 · 2.1K citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +16

Tezacaftor–Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis

Steven M. Rowe, Cori Daines, Felix C. Ringshausen et al. · New England Journal of Medicine · 2017 · 511 citations · Full text

Medicine, Genetics, Molecular Genetics +13

A phase 1/2 study of intrathecal heparan-N-sulfatase in patients with mucopolysaccharidosis IIIA

Simon Jones, Catherine Breen, Fiona Heap et al. · Molecular Genetics and Metabolism · 2016 · 126 citations · Full text

Medicine, Neurology, Pharmacology +13

A Prospective Natural History Study of Mucopolysaccharidosis Type IIIA

Elsa Shapiro, Igor Nestrašil, Kathleen Delaney et al. · The Journal of Pediatrics · 2016 · 113 citations · Full text

Medicine, Neurology, Pediatrics +17

Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials

Claire Keating, Lael M. Yonker, F. Vermeulen et al. · The Lancet Respiratory Medicine · 2025 · 89 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

1–5 of 26